AGMB
AgomAb Therapeutics NV - ADR

44
Mkt Cap
$366,200.00
Volume
619,791.00
52W High
$16.00
52W Low
$12.66
Price
$15.70
AGMB Fundamentals
Prev Close
$14.65
Open
$14.55
50D MA
$15.33
Beta
0.00
Avg. Volume
0.00
EPS (Annual)
-$2,001.86
P/B
0.00
Loading...
Loading...
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A

Frequently Asked Questions

What is Market Cap of AgomAb Therapeutics NV - ADR?
What is the 52-week high for AgomAb Therapeutics NV - ADR?
What is the 52-week low for AgomAb Therapeutics NV - ADR?
What is AgomAb Therapeutics NV - ADR stock price today?
What was AgomAb Therapeutics NV - ADR stock price yesterday?
What is the Price-to-Book ratio of AgomAb Therapeutics NV - ADR?
What is the 50-day moving average of AgomAb Therapeutics NV - ADR?

Latest AGMB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.